Palvella Therapeutics, Inc. (PVLA)
Palvella Therapeutics develops topical drug candidates for rare skin diseases and vascular malformations, aimed at patients and their doctors. It last closed at $144.35 on Nov 17, down 0.17% on the day. The average 12-month price target from 5 analysts is $237.80 (+64.7% from the last close), with a high of $246.00 and a low of $228.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in PVLA, 33% of them bullish and 67% bearish. In the past 30 days there were 1 dark pool print totaling $1.2M, the largest $1.2M.
Key Stats
Last 12 monthsNot reported for this period.
From PVLA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 5 analysts who set a price target on PVLA in the past 90 days. The average target is $237.80, with a high of $246.00 and a low of $228.00, compared with the last close of $144.35.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Leerink Partners | Initiated | Buy | $228 |
| Nov 9 | Canaccord Genuity | Maintained | Buy | $243 |
| Nov 6 | Oppenheimer | Maintained | Buy | $232 |
| Oct 12 | HC Wainwright & Co. | Maintained | Buy | $246 |
| Sep 21 | Chardan Capital | Maintained | Buy | $240 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 9% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 47). The nearest support is the swing low (Aug 31) at $143.47, and the nearest resistance the Pivot R1 at $145.79.
| RSI (14) | 47.01 | Middle of its range | Neutral |
| MACD | 4.22 | Below its signal line | Bearish |
| Stochastic | 27.8 | Middle of its range | Neutral |
| ADX (14) | 27.1 | Trending down | |
| Williams %R | -90.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -27.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −5.6% | Change over 10 sessions | Bearish |
| ATR (14) | $9.45 | Typical daily range, 6.5% of price |
| RSI (14) | 52.15 | Middle of its range | Neutral |
| MACD | 6.56 | Below its signal line | Bearish |
| Stochastic | 65.5 | Middle of its range | Neutral |
| ADX (14) | 20.1 | Weak trend | |
| Williams %R | -57.7 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 14.3 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −3.9% | Change over 10 sessions | Bearish |
| ATR (14) | $19.95 | Typical daily range, 13.8% of price |
What happened before
See how PVLA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in PVLA in the last 90 days.
Dark Pool
30DPVLA Institutional Ownership
Full report →- ▲107 buying vs 81 selling
- ▲Held by funds +3.3 pts
- ▲Funds holding +2
- ▼Superinvestors: 0 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 199 | 197 | +1.0% |
| In funds' top 10 | 6 | 6 | 0.0% |
| Held by funds | 99.7% | 96.4% | +3.3 pts |
| New / increased | 30 / 77 | 35 / 89 | −13.7% |
| Reduced / sold out | 53 / 28 | 43 / 19 | +30.6% |
| Put/call ratio | 0.11 | 2.00 | −94.4% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PVLA is in one of them and how their past PVLA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PVLA in an article yet. Here's the latest on the wider market.
About Palvella Therapeutics
Palvella Therapeutics is a biopharmaceutical company based in Wayne, Pennsylvania, that is developing topical treatments for rare skin diseases and vascular malformations where no approved therapies exist. Its lead candidate, a rapamycin gel called QTORIN rapamycin, is in clinical trials for microcystic lymphatic malformations and cutaneous venous malformations. The company also has a candidate in development for disseminated superficial actinic porokeratosis. Its target customers are patients with these conditions and the physicians who treat them.
- Headquarters
- Wayne, PA


